Can you answer the questions about this case ahead of joining Prof Sanyal's session by clicking here.

Ms. T, a 45-year-old woman with a BMI of 36 kg/m², has been recently diagnosed with metabolic-associated steatohepatitis (MASH) and type 2 diabetes. Despite taking metformin, she struggles with glycemic control. She's intrigued by the potential of GLP-1 receptor agonists but seeks more information on their effectiveness and how they might fit into her lifestyle.

Ms. T's busy schedule and frequent social engagements often involve dining out, making dietary changes challenging. She's motivated to improve her health but needs a sustainable approach that complements her lifestyle.

This program is funded by an independent grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.

Question:

A 40-year-old male with MASH is being monitored after initiating a new treatment regimen for his condition. What biomarker would be most useful to evaluate the immediate effectiveness of his treatment?

Answers: >> How did you do?? Answer's here << Or post your answer below!

1 - Hemoglobin A1c

2 - Serum albumin

3 - Gamma-glutamyl transferase (GGT)

4 - C-reactive protein (CRP)

5 - Alpha-fetoprotein (AFP)

Can you answer the questions about this case ahead of joining Dr Lizaola-Mayo's session by clicking here.

You're seeing a 54-year-old woman in your clinic today. She has a history of class I obesity and type 2 diabetes, currently managed with insulin. She's heard about fatty liver disease and is concerned she might be at risk. Her liver enzymes are normal, but given her risk factors, you decide to calculate a FIB-4 score, which comes back elevated. A subsequent FibroScan reveals stage 3 fibrosis, confirming your suspicions. You now face the challenge of explaining this diagnosis to your patient and discussing the best path forward, particularly considering the potential benefits of various therapeutic options for MASH.

This case highlights the prevalence of MASH and the importance of early detection and intervention. It also underscores the need for healthcare professionals to stay informed about the latest evidence-based treatment options for this condition. By participating in this educational program, you'll gain valuable insights into the management of MASH and develop the skills to provide optimal care for your patients.

This program is funded by an independent grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.

Can you answer the questions about these 2 cases written by Dr Balakrishnan? Join Dr Balakrishnan’s session, who will be chairing a discussion on this case in our MASH Academy

Case 1: Mrs J

Mrs. J is a 40-year-old woman presenting with a 10-year history of abnormal liver enzymes, including elevated ALT (90 U/L), AST (60 U/L), and alkaline phosphatase (130 U/L), along with a slightly low platelet count. She has a body mass index (BMI) of 30, indicating obesity, and has been diagnosed with prediabetes. Notably, Mrs. J reports no alcohol consumption.

Despite these persistent abnormalities, Mrs. J remains asymptomatic and has not been previously evaluated for liver disease. Her primary care physician is now concerned about the potential for underlying liver pathology.

Case 2: Mr D

Mr. D is a 55-year-old man with a long-standing history of type 2 diabetes and hypertension. He presents for a routine check-up with his primary care physician. His liver enzymes have always been within the normal range (ALT 29 U/L, AST 25 U/L) and his platelet count is 190,000/µL. However, his alkaline phosphatase is slightly elevated at 130 U/L. He has a body mass index (BMI) of 30, indicating obesity. Mr. D denies any alcohol consumption.

Despite normal liver enzymes and no symptoms of liver disease, Mr. D's physician is concerned about the elevated alkaline phosphatase and his risk factors.

This program is funded by an independent grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.